Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932272 | 0.90 | RPS6KB2 (0.51) | HPGDTRPV1TSHRRPS6KB2ALDH1A1 | |
| SCHEMBL25469437 | 0.85 | ALDH1A1 (0.53) | HPGDTRPV1RPS6KB2ALDH1A1LMNA | |
| SCHEMBL4903733 | 0.81 | HPGD (0.58) | HPGDTRPV1TSHRRPS6KB2ALDH1A1 | |
| SCHEMBL7474007 | 0.81 | HPGD (0.58) | HPGDTRPV1TSHRRPS6KB2ALDH1A1 | |
| SCHEMBL17203308 | 0.81 | TRPV1 (0.60) | HPGDTRPV1TSHRRPS6KB2ALDH1A1 | |
| SCHEMBL12781015 | 0.80 | ACACA (0.43) | HPGDRPS6KB2ALDH1A1MAPTLMNA | |
| SCHEMBL13838139 | 0.79 | HPGD (0.89) | HPGDTRPV1TSHRRPS6KB2ALDH1A1 | |
| SCHEMBL2224980 | 0.78 | HPGD (0.56) | HPGDTRPV1TSHRRPS6KB2ALDH1A1 | |
| SCHEMBL9602681 | 0.78 | FFAR1 (0.49) | RPS6KB2ALDH1A1MAPTLMNAPRNP | |
| SCHEMBL9024556 | 0.78 | HPGD (0.36) | HPGDTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HPGD 2186/4885TRPV1 3821/4885TSHR 1177/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | HPGD 2446/4885TRPV1 3863/4885TSHR 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.